A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140) Meeting Abstract
| Authors: | Beckermann, K.; Shah, N. J.; Vogelzang, N. J.; Mao, S. S.; Ornstein, M. C.; Hammers, H. J.; Gao, X.; McDermott, D. F.; Haas, N. B.; Yan, H. X.; Esquibel, V.; Rangwala, R. A.; Campbell, M. T. |
| Abstract Title: | A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304951 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS4599 |
| Notes: | Meeting Abstract: TPS4599 -- This meeting was also held virtually -- Source: Wos |
